Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ASCO GI 2023 > Oesophageal and Gastric Cancer > Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented by
Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
Conference
ASCO GI 2023
Trial
Phase 2, INFINITY
Doi
https://doi.org/10.55788/d5b393cc
    Neoadjuvant tremelimumab plus durvalumab displayed encouraging activity and a favourable safety profile in patients with microsatellite instability-high (MSI-H), resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC) in the phase 2 INFINITY trial

    In patients with GAC/GEJAC, MSI-H status has been linked to improved survival outcomes and a reduced benefit from chemotherapy [1]. On the other hand, immunotherapy is effective in MSI-H tumours [2]. Therefore, the combination of CTLA-4 inhibition and PD-L1 inhibition may result in the possibility of omitting chemotherapy or surgery in these patients.

    The multicentre, single-arm, phase 2 INFINITY trial (NCT04817826) assessed the efficacy and safety of tremelimumab plus durvalumab as neoadjuvant therapy in a cohort of 18 patients with MSI-H, mismatch repair deficient (dMMR), and EBV-negative resectable GAC/GEJAC [3]. In a second cohort, this therapy will be assessed as a definitive treatment for patients with this indication. In the neoadjuvant cohort, patients received a single dose of 300 mg tremelimumab and 1,500 mg durvalumab, every 4 weeks. The primary endpoint was the pathological complete response (pCR) with negative ctDNA after 12 weeks of treatment. Dr Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy) presented the findings [3].

    In total, 9 out of 15 evaluable patients achieved a pCR with negative ctDNA status (60%) prior to surgery. The major-complete pathological response rate (<10% viable cells) was 80%. According to Dr Pietrantonio, the global quality-of-life was preserved during the neoadjuvant treatment.

    Pre-operative treatment with tremelimumab and durvalumab was generally safe. In 3 patients, grade ≥3 immune-related adverse events (AEs) occurred; hepatitis, colitis, and pneumonitis, one case each. The most common grade 1 or 2 AEs were pruritis (22%), thyroiditis (22%), hepatitis (17%), and skin rash (17%).

    The combination of tremelimumab and durvalumab appeared to be safe and displayed encouraging activity in the current phase 2 trial. “Although larger studies are needed, chemotherapy-free, immune checkpoint inhibitor-based strategies will represent a standard-of-care in the molecular subgroup of MSI-H dMMR tumours in the foreseeable future,” argued Dr Pietrantonio. “Of course, optimal combinations and therapy duration should be further investigated.” This data is important for potential non-operative management as in locally advanced rectal cancer.

    1. Pietrantonio F, et al. JCO. 2019;37(35):3392–3400.
    2. Leone AG, et al. ESMO Open. 2022;7(1):100380.
    3. Pietrantonio F, et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). Abstract 358, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.

    Copyright ©2023 Medicom Medical Publishers



    Posted on